Kisspeptin for Women: Ovulation, Desire Research and the Cautions

A 2007 paper in the Journal of Clinical Endocrinology and Metabolism reported that the LH response to subcutaneous kisspeptin-54 in healthy women varied across the cycle and was greatest in the days before ovulation. In women, the same signal that drives the axis triggers ovulation, which is the basis of the IVF work. A 2011 study in the same journal reported that kisspeptin's effect differed between men and women, which is one reason findings in men, where most of the hormone studies were done, do not transfer directly.

Women whose periods have stopped because of low body weight, stress or over-training have a suppressed axis with intact ovaries. A 2009 study in the Journal of Clinical Endocrinology and Metabolism gave these women twice-daily subcutaneous kisspeptin-54 for two weeks: the axis was stimulated and then the response faded, a phenomenon called tachyphylaxis. A 2010 study in Clinical Pharmacology and Therapeutics gave twice-weekly injections for eight weeks and the response held.

What it shows. That spacing matters: continuous exposure blunts the response, intermittent exposure preserves it. This is why a kisspeptin schedule is built around gaps.

What it does not show. These were small physiological studies. They did not measure whether ovulation or fertility was restored, and they are not evidence that kisspeptin treats amenorrhea.

This is the most clinically developed line of work. A 2014 paper in the Journal of Clinical Investigation reported that a single subcutaneous injection of kisspeptin-54, given in place of the usual hCG trigger to women undergoing IVF, produced egg maturation in the large majority and was followed by healthy live births. A 2015 study in the Journal of Clinical Endocrinology and Metabolism extended this to women at high risk of ovarian hyperstimulation syndrome, and a 2017 phase 2 randomized trial in Human Reproduction tested a second dose in that group. The idea is to prompt a woman's own LH surge rather than substitute for it.

What it does not mean. Those were one- or two-dose triggers of kisspeptin-54, inside monitored IVF cycles, run by reproductive endocrinologists. That is fertility-clinic territory, not a wellness prescription, and kisspeptin at Pepti is not a fertility treatment.

A randomized, double-blind, placebo-controlled crossover trial in JAMA Network Open in 2022 enrolled premenopausal women with hypoactive sexual desire disorder (HSDD). A kisspeptin-54 infusion increased activation in sexual-processing brain regions on functional MRI, and the treatment was described as well tolerated, with no serious adverse events attributed to it. The trial is real and randomized; it is also small, single-session and intravenous, and it measured brain response rather than months of desire in daily life.

For comparison, PT-141 has two phase 3 trials in 1,267 premenopausal women with HSDD. When desire is the isolated complaint, PT-141 has by far the larger evidence base; kisspeptin is the one with a hormonal mechanism. See kisspeptin vs PT-141 and PT-141 for women.

The FDA's review found one study of a single subcutaneous kisspeptin-10 dose in healthy women and none by the intramuscular route. Most kisspeptin-10 hormone work was in men. There are no randomized trials of a subcutaneous kisspeptin-10 course taken over weeks, in women or men, for desire or anything else.

Kisspeptin is not used in pregnancy or breastfeeding; safety data is absent, and it acts directly on the reproductive axis. Supervised fertility-clinic use of kisspeptin-54 as a single trigger is not evidence that ongoing dosing is appropriate during a pregnancy. If you are actively trying to conceive or in an IVF cycle, that literature is a reason to treat kisspeptin with more caution, not less: raise it with the physician managing your fertility care first, and expect elective peptide therapy to pause. If you become pregnant on treatment, stop and contact your physician the same day. See do peptides affect fertility and can you take peptides while pregnant.

Because kisspeptin stimulates sex-hormone production, a hormone-sensitive condition, including a history of hormone-sensitive cancer, must be raised with the physician before starting kisspeptin or the EUPHORIA blend that contains it.

Kisspeptin acts on the axis that runs the cycle, and no trial has looked at what a weekday course does to cycle regularity or to hormonal contraception. Tell your physician which method you use, and report any change in your cycle.

No kisspeptin study in the live research enrolled women in the transition or after it. Low desire in these years is often driven by dryness, pain, sleep and mood rather than central drive, and no desire peptide addresses dryness or pain. If the transition is the driver, it belongs in its own conversation; Pepti does not prescribe menopausal hormone therapy. See peptides for menopause and peptides for women.

SSRIs and SNRIs, a new medication, sleep, pain with sex and relationship context all come before a peptide. Peptides for libido sets out what a physician looks at first.